Celestica (TSX:CLS) reported quarterly earnings of $0.52 per share which missed the analyst consensus estimate of $0.62 by 16.13 percent. This is a 48.57 percent increase over earnings of $0.35 per share from the same period last year.
Incyte Announces Results From SCRATCH-AD Trial Demonstrating Substantial And Rapid Itch Reduction In Patients With Mild-Moderate Atopic Dermatitis Treated With Opzelura Cream
– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28Incyte (NASDAQ:INCY) today announced new data from the Phase 2
